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Abstract
Background: Bacterial meningitis is associated with significant burden in Brazil. In 2010, both 10-valent pneumococcal
conjugate vaccine and meningococcal capsular group C conjugate vaccine were introduced into the routine vaccination
schedule. Haemophilus influenzae type b vaccine was previously introduced in 1999. This study presents trends in
demographics, microbiological characteristics and seasonality patterns of bacterial meningitis cases in Brazil from 2000 to
2010.
Methods and Findings: All meningitis cases confirmed by clinical and/or laboratory criteria notified to the national
information system for notifiable diseases between 2000 and 2010 were analyzed. Proportions of bacterial meningitis cases
by demographic characteristics, criteria used for confirmation and etiology were calculated. We estimated disease rates per
100,000 population and trends for the study period, with emphasis on H. influenzae, N. meningitidis and S. pneumoniae
cases. In the decade, 341,805 cases of meningitis were notified in Brazil. Of the 251,853 cases with defined etiology, 110,264
(43.8%) were due to bacterial meningitis (excluding tuberculosis). Of these, 34,997 (31.7%) were due to meningococcal
disease. The incidence of bacterial meningitis significantly decreased from 3.1/100,000 population in 2000–2002 to 2.14/
100,000 in 2009–2010 (p,0.01). Among cases of meningococcal disease, the proportion of those associated with group C
increased from 41% in 2007 to 61.7% in 2010, while the proportion of group B disease progressively declined. Throughout
the study period, an increased number of cases occurred during winter.
Conclusions: Despite the reduction in bacterial meningitis incidence during the last decade, it remains a significant
healthcare issue in Brazil. Meningococcal disease is responsible for the majority of the cases with group C the most common
capsular type. Our study demonstrates the appropriateness of introduction of meningococcal vaccination in Brazil.
Furthermore, this study provides a baseline for future evaluation of the impact of the vaccines introduction in Brazil and
changes in disease epidemiology.
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Introduction
In Brazil, surveillance of meningitis is based on mandatory
notification of all suspected cases occurring in the public or private
healthcare systems, including healthcare units and diagnostic
laboratories. Cases are notified to the national information system
for notifiable diseases (‘‘Sistema de Informac¸a˜o de Agravos de
Notificac¸a˜o’’ - SINAN), a national case-based information system
managed by the Brazilian Ministry of Health. SINAN was
implemented countrywide in the early 90s and has gone through
several improvements, the last one in 2007 when it shifted to an
internet-based data transfer system along with other minor
changes [1].
Meningitis surveillance is critical for the timely detection of
epidemics and for determining the local disease burden, so that
proper prevention and control strategies can be implemented. The
main pathogens causing bacterial meningitis are H. influenzae, N.
meningitidis and S. pneumoniae, for which conjugate vaccines are now
available globally. In this regard, H. influenzae type b (Hib) vaccine
was introduced into the routine vaccination schedule in Brazil in
1999, and more recently, both 10-valent pneumococcal (PCV10)
and meningococcal capsular group C (MenC-V) conjugate
vaccines were introduced in 2010. This study describes the
epidemiology of bacterial meningitis across all age groups in Brazil
in the decade prior to the introduction of these new vaccines, with
a particular focus on meningococcal disease. The epidemiological
scenario that motivated the incorporation of these new vaccines
into the routine schedule, taking into consideration both the
optimal age for vaccination and the potential coverage against
prevalent serogroups is discussed, so that future studies can benefit
from our baseline assessment in order to measure the impact of
these interventions.
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Methods
Ethics Statement
Ethical approval for this study was obtained from the Ethical
Committee of Hospital Sı´rio-Libaneˆs, Sa˜o Paulo, Brazil (Comissa˜o
de E´tica em Pesquisa - CAAE: 01063212.1.0000.5461 - 01/03/
2012). Nominal information was used only for record-linkage
purposes in order to clean the database of duplications. Since this
is an observational analysis of a national secondary database,
subject’s informed consent was waived from the Institutional
Ethics Committee.
Methods
All meningitis and meningococcemia cases confirmed by clinical
and/or laboratory criteria reported to SINAN between 2000 and
2010 were included in the study. Case-based variables available for
analysis include demographic, clinical and microbiological infor-
mation.
Laboratory and/or clinical/epidemiologic criteria were consid-
ered for definition of meningitis cases, following the recommen-
dations provided by the Brazilian Health Ministry guidelines [2].
Accordingly, a suspected case was defined as any children and
adults of any age, for whom the attending physician suspected of
meningitis. Clinical signs and symptoms included fever, headache,
vomit, neck stiffness, signs of meningeal irritation, seizures, and/or
rash. In children younger than 1 year of age, unspecific symptoms
were considered. Laboratory confirmation included the following
specific methods: culture or antigen detection in the cerebrospinal
fluid (CSF), including latex or contraimmuno-electrophoresis tests.
Although other laboratory confirmation tests could be used,
including Enzyme-linked immunosorbent assay (ELISA), poly-
merase chain reaction (PCR) and immunofluorescence, these are
mostly used in academic institutions and are not routinely
available. Suspected cases that had contact to a laboratory-
confirmed case were confirmed through clinical/epidemiological
criteria. Meningococcemia suspected cases could be confirmed by
CSF inspection showing gram-negative diplococcic and petequiae.
As SINAN is a nationwide system, which sensitivity and
representativeness for meningitis has been demonstrated to be
high [3,4], in this analysis we refer to notification rates as incidence
rates.
Annual bacterial meningitis incidence rates per 100,000
population, by age group, gender, pathogen, and serogroup were
calculated. Population estimates were provided by the Brazilian
Institute of Geography and Statistics (‘‘Instituto Brasileiro de
Geografia e Estatı´stica’’ – IBGE). Age groups considered were
those recommended by World Health Organization (WHO) for
assessing meningitis surveillance data: 0–23 months, 2–4 years, 5–
14 years, 15–29 years, 30–45 years and 45 years and more [5].
Monthly population data by age groups were estimated by linearly
interpolating the mid-year estimates for the months in between.
All analyses were done using Stata 12 (Stata Corporation, Texas,
USA). Temporal trends were assessed using the non-parametrical
test for trend across ordered groups (nptrend command in Stata),
with a P value considered statistically significant when below 0.05.
SINAN upgraded its operational system in 2006/2007. For
some months the two systems were running in parallel, so that
cases could have been notified to both systems, generating
duplicate records. Duplicate records may also have been generated
when cases were transferred within (e.g. one notification from the
emergency room and another from the intensive care unit) or in
between health care units. In order to identify and exclude
duplicated cases from our analysis, a three-step process was
applied. First, an in-house deterministic record linkage algorithm,
similar to the one validated by Pacheco et al [6] was used to find
records that belonged to the same patient. Next, we considered
that consecutive records of the same patient with an interval of up
to seven days between the dates of entry belonged to the same
episode of disease. We then discarded repeated records of the same
episode of disease. For cases that had different disease etiology
information recorded in the duplicated records, we applied the
following exclusion priority rules: missing values.unspecified.
other etiology (parasitic and fungal diseases).viral.tuberculos-
is.H. influenzae.pneumococcal.meningococcemia.meningo-
coccal meningitis.meningococcal meningitis with meningococce-
mia. Records with higher priority for exclusion were removed
from the analysis.
Guidelines for completion of some variables were modified in
2006/2007. Most notably, the main criteria used for case
confirmation, i.e. whether it was based on laboratory or clinical/
clinical-epidemiological findings, became more stringent. As a
consequence, a decrease in the number of cases classified as
‘‘unspecified bacteria’’ (cases marked as having a bacterial disease
due to ‘‘other’’ bacteria for which no etiology was specified in the
corresponding field) and an increase in the number of cases
classified as ‘‘unspecified etiology’’ was observed. We thus present
data on the criteria used for diagnosis by pathogen only for 2007–
2010.
As information on N. meningitidis capsular groups only started to
be recorded after the system upgrade in 2007, we present data on
N. meningitidis capsular groups by notification year and age groups
only from 2007 onwards. Information on S. pneumoniae serotypes is
not available in SINAN.
Results
Over the 11-year period, 341,805 cases of meningitis and
meningococcemia were notified to SINAN, and of these 327,449
(95.8%) had CSF collected. Of these, 251,853 (73.7%) cases had a
defined etiology, and 89,952 (26.3%) were pathogen unspecified.
Of the 251,853 cases with a defined etiology, 110,264 (43.8%)
were classified as bacterial meningitis cases (excluding tuberculo-
sis), 125,881 (49.9%) as aseptic, 11,546 (4.6%) as fungal/parasitic,
and 4,162 (1.7%) as tuberculosis.
Of the 110,264 bacterial meningitis cases, 34,997 (31.7%) were
due to N. meningitidis, 13,209 (12%) were due to S. pneumoniae, 2,152
(2%) to H. influenzae type b, 4,749 (4.3%) to other bacteria, and
55,157 (50%) had no bacteria specified.
From the 34,997 meningitis cases due to N. meningitidis, 9,999
(28.6%) were classified as meningococcemia, 13,720 (39.2%) as
meningococcal meningitis, 11,278 (32.2%) as meningococcemia
combined with meningococcal meningitis. We will refer to these
three combined categories as cases of meningococcal disease.
Among the 4,749 cases with other bacteria specified, the most
common ones were Staphylococcus (including S. aureus, S. epidermidis,
and Staphylococcus sp.) (988 cases, 20.8%), Streptococcus (including S.
pyogenes, S. agalactie, and Streptococcus sp.) (656 cases, 13.8%), and
Acinetobacter (including A. baumannii, and Acinetobacter sp.) (295 cases,
6.2%). Only 47 (1%) cases were due to Listeria monocytogenes, of
which only 3 were in the neonatal period.
Of the 110,264 bacterial meningitis cases, 30,237 occurred from
2007 onwards. Of these, 11,097 (36.7%) were confirmed by
culture, 7,529 (24.9%) by cytochemical analysis, 5,291 (17.5%) by
clinical/epidemiological criteria, 4,142 (13.7%) by antigen detec-
tion methods and 2,178 (7.2%) by bacterioscopy. These percent-
ages add up to 100% as in SINAN only one single methodology
representing the main method used for case confirmation is
informed for each case. During this period, the proportion of cases
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confirmed by culture, bacterioscopy and by clinical symptoms
remained relatively stable, whereas cases confirmed by antigen
detection methods increased from 10.2% in 2007 to 17.9% in
2010 and cases confirmed by cytochemical analysis decreased
from 29% in 2007 to 22% in 2010. Nonetheless, the main method
used for diagnosis varied according to the pathogen (Figure 1).
While the diagnosis of meningococcemia was mostly based on
clinical/epidemiological criteria, the diagnosis of meningitis due to
unspecified bacteria was, as expected, mostly dependent on CSF
cytochemical results. Culture contributed to the diagnosis of less
than 40% of meningococcemia/meningitis due to N. meningitidis
and to over 60% for the other specified bacteria.
Figure 2 shows that the age group of the bacterial meningitis
cases varied according to the pathogen. Almost half of the cases
due to H. influenzae were under two years of age, while for the other
pathogens this proportion varied in between 20% and 30%. The
proportion of cases in adults aged 30 years and over was higher for
cases due to S. pneumoniae than for those due to N. meningitidis and
H. influenzae, and similar to the proportion for all the other
specified bacteria combined (around 40%).
Incidence rates of meningitis cases caused by N. meningitidis, S.
pneumoniae and H. influenzae, stratified by age group, gender, and
pathogen are presented in Table 1. Cases of meningococcal
disease still predominate as compared to the other bacteria. A 30%
decline in bacterial meningitis incidence overall is observed from
2000–2002 (3.09 cases/100,000 population) to 2009–2010 (2.15
cases/100,000 population) (p,0.01). Considering the various
bacterial etiologies, the most significant proportional decline was
observed for H. influenzae cases (72%), which is a result of Hib
vaccine introduction in 1999. Incidence rates were significantly
higher in males for all the three pathogens analyzed. Disease
incidence was higher in children below 5 years of age for all the
three pathogens analyzed, with a lower incidence in young adults
and again an incidence peak in the age group of 45 years of age
and older, mainly represented by S. pneumoniae cases.
The incidence of meningitis cases due to N. meningitidis, S.
pneumoniae and H. influenzae decreased over time. A marked
seasonal pattern was observed with increased incidence during
autumn-winter periods (from May to October) and decreasing in
the summer. Incidence rates for all pathogens were markedly
higher in children younger than 2 years of age. In this age group,
we can observe that the incidence of N. meningitidis, more evidently,
and of H. influenzae had a decreasing trend up to 2006, after which
they tended to stabilize. In this age group we also observed that S.
pneumoniae meningitis, in particular, decreased after 2010 (Figure 3).
Out of the 11,037 meningococcal disease cases notified from
2007 onwards, 6,137 (55.6%) had no capsular group information
recorded, 3,588 (32.5%) were due to group C (MenC), 949 (8.6%)
were due to group B (MenB), 264 (2.4%) to group W135 (MenW)
and only 99 (0.9%) were due to the other groups (A, D, X, Y, Z
and 29E). If we consider only the 5,528 cases (out of the 11,037)
for which the criteria used for diagnosis was recorded as culture,
latex agglutination or PCR, the proportion of those with no
information about capsular group is reduced to 27.5%, and more
than half (52.6%) were due to MenC. This proportion progres-
sively increased from 41% in 2007 to 61.7% in 2010, while the
proportion of MenB progressively decreased (Table 2). The
capsular group distribution did not vary by age (Figure 4).
Discussion
Bacterial meningitis is a significant cause of death and disability
in children below five years of age in the world [7–12]. In most
countries N. meningitidis is a leading cause of meningitis and
fulminant sepsis, but, according to the WHO, no reliable global
disease burden estimate is currently available [13]. Invasive
meningococcal infections are usually caused by serogroups A, B,
Figure 1. Proportion of bacterial meningitis cases notified to SINAN in Brazil from 2007 to 2010 by criteria used for case
confirmation, according to pathogen. Antigen detection methods include latex agglutination, counterimmunoelectrophoresis (CIE) and
polymerase-chain reaction (PCR).
doi:10.1371/journal.pone.0064524.g001
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C, W135, X, or Y. Their relative prevalence varies with time and
geographic location. While serogroup A meningococci cause large
epidemics in sub-Saharan Africa, serogroups B and C organisms
are responsible for sporadic cases and localized disease outbreaks
worldwide [13].
Our study used secondary data to evaluate meningitis epidemi-
ology and disease burden in Brazil. This allowed us to analyze data
from a long time series, which is representative of the whole
population. Despite a considerable decline in the number of cases
in the last decade, the three main pathogens are still responsible
for a significant incidence, mainly in children below four years of
age and in particular N. meningitidis. In addition, we demonstrated
that serogroup C is the most important capsular type among N.
meningitidis cases in Brazil.
Our analysis demonstrates a lower incidence of bacterial
meningitis in Brazil when compared with other low or middle-
income countries. While in India, a higher incidence of
meningococcal disease, mostly due to epidemics caused by MenA
[14] has been described, our study demonstrate an increased
incidence of MenC and decline in the number of cases of MenB in
Brazil. Interestingly, the incidence of meningococcal disease in
India seems to be lower than the caused by other agents as S.
pneumoniae or H. influenzae [14]. In Cuba, Pe´rez et al demonstrated
overall incidence rates of bacterial meningitis similar to those
described in our study for Brazil. However, most cases in Cuba are
due to S. pneumoniae, and periodic vaccination campaigns may have
been responsible for the lower proportion of cases caused by N.
meningitidis [15].
When compared to developed countries, the incidence of
bacterial meningitis in Brazil is still high. Data from the USA prior
to PCV introduction demonstrate a reduction in the number of
meningitis cases from 1998 to 2007, with a higher proportion of
cases due to S. pneumoniae. The age distribution of cases in the USA
was similar to the observed in our study, with a reduction of
incidence in young adults and another peak of incidence in older
persons, mainly due to pneumococcal disease [10]. In a 31-year
descriptive study, Stanton et al characterized the cases of
meningococcal disease admitted to a tertiary children center in
England and identified a significant proportion of cases caused by
MenB with the majority of cases occurring below 4 years of age. In
this study, the proportion of cases due to MenC increased
significantly until the year 2000, when meningococcal vaccination
reduced the number of cases to very low levels [16].
Prior to Hib vaccine introduction in Brazil, the epidemiology of
bacterial meningitis was characterized by the predominance of
meningococcal disease and H. influenzae meningitis over cases
caused by S. pneumoniae [17,18]. Various Brazilian studies focusing
on N. meningitidis confirms our findings in term of serogroups most
commonly identified. While some authors demonstrate the
predominance of MenB cases in the late 90’s and early 2000
[19,20], more recent evaluations indicate that most cases of
meningococcal disease in the last decade were caused by MenC
[21].
The introduction of Hib vaccination significantly reduced the
incidence of invasive disease caused by H. influenzae in several high-
income and developing countries [22–24]. In Brazil, a surveillance
study carried out in Salvador, Bahia, demonstrated a considerable
reduction in the incidence of Hib meningitis mainly in children
below one year of age (from 60.9 to 3.1 cases per 100,000
population) [25]. National data from SINAN demonstrated that,
prior to Hib vaccine introduction in 1999, H. influenzae was
responsible for approximately 1,700 meningitis cases every year,
with an average annual incidence in all age groups of 1.1 cases/
100,000 population in Brazil [26]. After vaccine introduction, a
90% reduction of cases, incidence and deaths was demonstrated.
Our study confirms these findings, with a demonstrated 72%
incidence reduction of H. influenzae meningitis in the entire country
in the decade after introduction of the vaccine, most notably in
children below two years of age. The almost complete exclusion of
Hib as a cause of invasive disease is associated, however, with the
phenomenon of serotype replacement. Ribeiro et al observed in
their sample a transient increase in the number of cases caused by
Figure 2. Proportion of bacterial meningitis cases notified to SINAN in Brazil from 2000 to 2010 by age group, according to the
pathogen.
doi:10.1371/journal.pone.0064524.g002
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H. influenzae type a [25]. Other subsequent study demonstrated a
significant increase in the number of non-b and nontypeable H.
influenzae meningitis isolates in the years 2000–2008 in a national
reference laboratory [23]. This fact may be due to improvements
in the surveillance of this pathogen in the period.
Previous reports demonstrated the considerable impact of
introducing both pneumococcal and meningococcal vaccine into
the routine schedule on the incidence of meningitis in several
countries [10,27–29]. Currently licensed meningococcal conjugate
vaccines are either monovalent (A or C) or quadrivalent
(A,C,Y,W-135) [13]. MenC-V was first licensed in England in
Table 1. Incidence rates of meningitis due to N. meningitidis, S. pneumoniae e H. influenzae per 100,000 population in Brazil, 2000
to 2010, stratified by age group, gender, and pathogen.
Rates/100,000 population
Characteristic 2000–2002 2003–2005 2006–2008 2009–2010 p-value for trend*
Pathogen
All three pathogens 3.10 2.63 2.20 2.14 0.003
Neisseria meningitidis 2.21 1.81 1.48 1.51 0.004
Meningococcemia 0.57 0.52 0.44 0.49 0.010
Meningococcal meningitis 0.86 0.72 0.59 0.57 0.004
Meningococcemia+meningitis 0.78 0.58 0.45 0.45 0.003
Haemophylus influenzae 0.21 0.08 0.07 0.06 0.005
Streptococcus pneumoniae 0.67 0.74 0.65 0.58 0.069
Age group
Neisseria meningitidis
0–23 m 9.81 7.68 6.29 7.05 0.007
2–4 y 12.55 12.45 10.47 8.54 0.078
5–14 y 3.34 2.85 2.35 2.35 0.004
15–29 y 1.14 0.98 0.88 1.06 0.053
30–45 y 0.39 0.39 0.36 0.44 0.751
45+ 0.6 0.57 0.58 0.62 0.583
Haemophylus influenzae
0–23 m 1.92 0.65 0.55 0.57 0.009
2–4 y 1.49 0.4 0.54 0.35 0.043
5–14 y 0.15 0.08 0.06 0.06 0.009
15–29 y 0.03 0.01 0.02 0.02 0.544
30–45 y 0.02 0.02 0.01 0.02 0.204
45+ 0.04 0.04 0.03 0.03 0.010
Streptococcus pneumoniae
0–23 m 4.09 3.74 3.45 2.98 0.003
2–4 y 1.16 1.64 1.5 1.39 0.078
5–14 y 0.48 0.56 0.49 0.45 0.686
15–29 y 0.32 0.37 0.34 0.29 0.341
30–45 y 0.28 0.33 0.3 0.24 0.583
45+ 0.7 0.86 0.73 0.72 0.751
Gender
Neisseria meningitidis
Male 2.45 2.05 1.68 1.74 0.004
Female 1.96 1.58 1.3 1.28 0.004
Haemophylus influenzae
Male 0.24 0.1 0.07 0.08 0.009
Female 0.19 0.06 0.07 0.04 0.007
Streptococcus pneumoniae
Male 0.84 0.88 0.81 0.7 0.057
Female 0.51 0.6 0.49 0.46 0.175
*Notification years (and not notification sub-periods shown on this table) were used as the group variable of the non-parametric tests.
doi:10.1371/journal.pone.0064524.t001
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1999 for children aged 2 months and older and adults. In 2005,
the quadrivalent meningococcal conjugate vaccine was licensed for
use in adolescents and adults in the USA. Large scale MenC-V
vaccination has drastically reduced the incidence of MenC-disease
in several countries [13,16,27].
Most countries in the world implemented meningococcal
outbreak control strategies including vaccination of those at risk
or exposed during the outbreak. As part of the national disease
prevention and control strategies, Brazil has an effective meningitis
control program, which includes timely detection of outbreaks,
chemoprophylaxis of cases’ contacts and vaccination for outbreak
control when appropriate [2,30]. Since mid-70’s, vaccines used for
outbreak control in the country have been the polysaccharide
vaccine types A and C.
In addition to outbreak control, many countries have intro-
duced meningococcal vaccination to high risk individuals such as
travelers to areas in which meningococcal disease is hyperendemic
or epidemic, patients with anatomic or functional asplenia, and
patients with humoral immunodeficiencies, particularly those with
complement deficiency [31,32]. In Brazil, MenC vaccine is
provided since 2003 to the above groups, and also to HIV-
infected individuals younger than 13 years, patients with cochlear
implant, and patients with storage diseases. Efficient outbreak
control strategies and vaccination of high-risk groups might be at
least partially responsible for the decreasing trends observed for
meningococcal disease rates during the initial period of our study.
A decreasing trend in the number of newborns from 2006 onwards
might be somewhat responsible for the stabilization of the
incidence rates after this year.
Figure 3. Monthly incidence rates of meningitis due to N. meningitidis, S. pneumoniae and H. influenzae per 100,000 population, by
age-group, in Brazil, 2000 to 2010. Panel A: All age groups combined, Panel B: Children aged 0 to 23 months.
doi:10.1371/journal.pone.0064524.g003
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World Health Organization recommends the introduction of
large-scale meningococcal vaccination programs in countries with
high (,10 cases/100,000 population/year) or intermediate (2–10
cases/100,000 population/year) endemic rates of invasive menin-
gococcal disease [13]. Regarding pneumococcal vaccination, a
heptavalent pneumococcal conjugate vaccine (PCV7) was licensed
in 2000 followed by 10-valent (PCV10) and 13-valent (PCV13)
PCVs in 2009 and 2010. WHO also recommended the use of
these vaccines, especially in countries with high child mortality
[33].
Thus, it is expected that the recent introduction of MenC-V
[34] and PCV10 [35] in the Brazilian routine immunization
schedule will substantially reduce the incidence of these diseases in
the coming years. Despite its very recent introduction, it was
demonstrated that PCV10 introduction in 2010 resulted in a
significant early impact in reducing pneumonia cases in Brazil
[36]. Similar early impact in pneumococcal meningitis cases may
be demonstrated in future studies. Likewise, it will be important to
evaluate pneumococcal serotype replacement in the country
following PCV10 introduction. Current evidence does not indicate
that significant replacement takes place after meningococcal
conjugate vaccine introduction [37].
There are several limitations to our study, mainly due to the use
of secondary data sources. Studies that make use of secondary
surveillance data such as SINAN are very much contingent on the
quality and methods used to collect and classify the data [38].
Surveillance information are much more incomplete and subject
to systematic and random errors when compared with data from
observational studies, especially prospective ones. Secondary data
usually do not allow significant characterization of the study
population and selected important information are not adequately
represented [4]. On this account, we did not have etiologic
information on a significant percentage of patients and outcome
data was not available for 74% of the reported cases. Thus, we did
not consider the reported 4.8% case fatality ratio to be
representative of the population, even as it is more likely that
cases that died had their outcome reported. The lack of availability
of quality survival information due to incompleteness of the forms
is an important limitation of our analysis.
Is SINAN meningitis data good enough for what it is expected
to do? Despite its limitations, secondary surveillance data enabled
us to track variations in the incidence of the disease and prevalent
serogroups, and highlight any significant trends. Also, the
availability of such data can be useful to compare observed and
Figure 4. Distribution of meningococcal disease cases by capsular subgroup (n=11,037) in Brazil, 2007 to 2010.
doi:10.1371/journal.pone.0064524.g004
Table 2. Distribution of laboratory confirmed N. meningitidis cases by capsular group in Brazil, 2007 to 2010.
Year Capsular group n (%) Total
A B C X Y Z W 135 29 E No information
2007 1 (0.1) 232 (19.4) 491 (41) 0 (0) 8 (0.7) 0 (0) 32 (2.7) 0 (0) 433 (36.1) 1,197
2008 5 (0.4) 217 (16.4) 665 (50.2) 1 (0.1) 9 (0.7) 1 (0.1) 66 (5) 1 (0.1) 356 (27.0) 1,321
2009 8 (0.6) 183 (13.5) 736 (54.1) 0 (0) 15 (1.1) 0 (0) 53 (3.9) 0 (0) 365 (26.8) 1,360
2010 4 (0.2) 178 (10.8) 1,018 (61.7) 0 (0) 11 (0.7) 0 (0) 70 (4.2) 3 (0.2) 366 (22.2) 1,650
Total 18 (0.3) 810 (14.7) 2,910 (52.6) 1 (0) 43 (0.8) 1 (0) 221 (4) 4 (0.1) 1,520 (27.5) 5,528
Laboratory criteria included culture, latex agglutination or polymerase chain reaction.
doi:10.1371/journal.pone.0064524.t002
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projected values as a strategy to evaluate the impact of
interventions like vaccination on disease burden.
Conclusion
Meningococcus and pneumococcus are still responsible for a
significant burden of bacterial meningitis in Brazil. MenC is the
most prevalent serogroup among meningococcal disease cases,
indicating the appropriateness of MenC vaccine introduction in
Brazil. In this regard, this study provides important baseline for
future evaluation of the impact of PCV10 and MenC vaccine
initiation and changes in disease epidemiology, including etiology,
serogroup, and age distribution of cases.
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